Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181627 | 0.81 | ALOX5AP (0.47) | POLBALOX5APFEN1KDM4E | |
| SCHEMBL7409193 | 0.81 | CHRNB2 (0.54) | GPR119 | |
| SCHEMBL7453857 | 0.81 | CHRNB2 (0.54) | GPR119 | |
| SCHEMBL27462042 | 0.81 | GPR119 (0.48) | GPR119POLBALOX5APFEN1 | |
| SCHEMBL29007782 | 0.81 | SSTR4 (0.47) | POLBALOX5APFEN1KDM4E | |
| SCHEMBL30181179 | 0.81 | ALOX5AP (0.46) | UCHL1GPR119POLBALOX5APFEN1 | |
| SCHEMBL14334945 | 0.81 | ALOX5AP (0.50) | UCHL1GPR119POLBALOX5APFEN1 | |
| SCHEMBL29008012 | 0.81 | SSTR4 (0.47) | GPR119POLBALOX5APFEN1KDM4E | |
| SCHEMBL15916877 | 0.81 | ALOX5AP (0.56) | GPR119POLBALOX5APFEN1KDM4E | |
| SCHEMBL14334638 | 0.81 | ALOX5AP (0.50) | UCHL1GPR119POLBALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | UCHL1 2815/4885GPR119 223/4885POLB 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.